Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2016 | Evaluation 17p del CLL patients treated with ibrutinib: cross-study analysis of treatment outcomes

Jeffrey Jones • 9 Jun 2016
EHA 2016
Chronic Lymphocytic Leukemia Ibrutinib

Press brief by Jeffrey Jones, MD, MPH of the The Ohio State University, Columbus, OH, on a cross-study analysis of treatment outcomes of 243 patients with 17p del CLL treated with ibrutinib at the 2016 Annual Meeting of the European Association of Hematology (EHA), held in Copenhagen, Denmark.

More from Jeffrey Jones

2:42
Current thought on treating chronic lymphocytic leukemia
Jeffrey Jones • 9 Jun 2016
3:46
The characteristics and mode of action of ibrutinib for CLL
Jeffrey Jones • 9 Jun 2016

Related Videos

3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
3:18
A Phase I study of JBH492, an anti-CCR7 antibody-drug conjugate, in lymphoid malignancies
Pau Abrisqueta • 5 Apr 2024
0:44
Early detection and interception across hematological cancers
Irene Ghobrial • 8 Apr 2024
1:21
Monoclonal B-cell lymphocytosis: a disease to be (or not to be)
Paolo Ghia • 7 Apr 2024
The content of VJHemOnc is intended for healthcare professionals